The short version of regulatory status fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-02 and is reviewed periodically as new material appears.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
== Interactions == Unlike cimetidine, the first H2 antagonist, famotidine has a minimal effect on the cytochrome P450 enzyme system and does not appear to interact with as many drugs as other medications in its class. Some exceptions include antiretrovirals such as atazanavir, chemotherapeutics such as doxorubicin, and antifungal medications such as itraconazole.
== Bibliography == Move That Mountain (1976), ISBN 978-0-88270-164-6 Eight Keys to Success (1980), ISBN 978-0-89221-071-8 I Was Wrong (1996), ISBN 978-0-7852-7425-4 Prosperity and the Coming Apocalypse (1998), ISBN 978-1-4185-5422-4 The Refuge: The Joy of Christian Community in a Torn-Apart World (2000), ISBN 978-1-4185-5423-1 Time Has Come: How to Prepare Now for Epic Events Ahead (2014), ISBN 978-1-61795-134-3 You Can Make It: God's Faithfulness in Dark Times-Past, Present and Future (2021) ISBN 978-1-63641-047-0
where the nuclear binding energy is proportional to the nuclear volume, while nucleons near the surface interact with fewer nucleons, reducing the effect of the volume term. According to Lilley, "For all naturally occurring nuclei, the surface-energy term dominates and the nucleus exists in a state of equilibrium." The negative contribution of Coulomb energy arises from the repulsive electric force of the protons. The symmetry term arises from the fact that effective forces in the nucleus are stronger for unlike neutron-proton pairs, rather than like neutron–neutron or proton–proton pairs. The pairing term arises from the fact that like nucleons form spin-zero pairs in the same spatial state. The pairing is positive if N and Z are both even, adding to the binding energy. In fission there is a preference for fission fragments with even Z, which is called the odd–even effect on the fragments' charge distribution. This can be seen in the empirical fragment yield data for each fission product, as products with even Z have higher yield values. However, no odd–even effect is observed on fragment distribution based on their A. This result is attributed to nucleon pair breaking. In nuclear fission events the nuclei may break into any combination of lighter nuclei, but the most common event is not fission to equal mass nuclei of about mass 120; the most common event (depending on isotope and process) is a slightly unequal fission in which one daughter nucleus has a mass of about 90 to 100 daltons and the other the remaining 130 to 140 daltons.
== Further reading == Hunt, Chris; et al. (August 28, 2023). "Shanidar et ses fleurs? Reflections on the palynology of the Neanderthal 'Flower Burial' hypothesis". Journal of Archaeological Science. 159 105822. Bibcode:2023JArSc.159j5822H. doi:10.1016/j.jas.2023.105822. S2CID 261325698. Pettitt, Paul; White, Mark (2012). The British Palaeolithic: hominin societies at the edge of the Pleistocene world. London: Routledge. ISBN 978-0-415-67454-6. Romagnoli, Francesca; Rivals, Florent; Benazzi, Stefano (2022). Updating Neanderthals: Understanding Behavioural Complexity in the Late Middle Palaeolithic. Academic Press. ISBN 978-0-12-821429-9. Stringer, C.; Gamble, C. (1993). In search of the Neanderthals. Thames and Hudson. ISBN 0-500-05070-8. Sykes, Rebecca Wragg (2020). Kindred: Neanderthal Life, Love, Death and Art. London: Bloomsbury Sigma. ISBN 978-1-4729-3749-0.
Rn(g) + 2 [O2]+[SbF6]−(s) → [RnF]+[Sb2F11]−(s) + 2 O2(g) For this reason, antimony pentafluoride together with chlorine trifluoride and N2F2Sb2F11 have been considered for radon gas removal in uranium mines due to the formation of radon–fluorine compounds. Radon compounds can be formed by the decay of radium in radium halides, a reaction that has been used to reduce the amount of radon that escapes from targets during irradiation. Additionally, salts of the [RnF]+ cation with the anions SbF6−, TaF6−, and BiF6− are known. Radon is also oxidised by dioxygen difluoride to RnF2 at 173 K (−100 °C; −148 °F). Radon oxides are among the few other reported compounds of radon; only the trioxide (RnO3) has been confirmed. The higher fluorides RnF4 and RnF6 have been claimed, are calculated to be stable, but have not been confirmed. They may have been observed in experiments where unknown radon-containing products distilled together with xenon hexafluoride: these may have been RnF4, RnF6, or both. Trace-scale heating of radon with xenon, fluorine, bromine pentafluoride, and either sodium fluoride or nickel fluoride was claimed to produce a higher fluoride as well which hydrolysed to form RnO3. While it has been suggested that these claims were really due to radon precipitating out as the solid complex [RnF]2+[NiF6]2−, the fact that radon coprecipitates from aqueous solution with CsXeO3F has been taken as confirmation that RnO3 was formed, which has been supported by further studies of the hydrolysed solution.
Sources: en.wikipedia.org
== Membrane separation processes == Membrane separation processes have a very important role in the separation industry. Nevertheless, they were not considered technically important until the mid-1970s. Membrane separation processes differ based on separation mechanisms and size of the separated particles. The widely used membrane processes include microfiltration, ultrafiltration, nanofiltration, reverse osmosis, electrolysis, dialysis, electrodialysis, gas separation, vapor permeation, pervaporation, membrane distillation, and membrane contactors. All processes except for pervaporation involve no phase change. All processes except electrodialysis are pressure driven. Microfiltration and ultrafiltration is widely used in food and beverage processing (beer microfiltration, apple juice ultrafiltration), biotechnological applications and pharmaceutical industry (antibiotic production, protein purification), water purification and wastewater treatment, the microelectronics industry, and others. Nanofiltration and reverse osmosis membranes are mainly used for water purification purposes. Dense membranes are utilized for gas separations (removal of CO2 from natural gas, separating N2 from air, organic vapor removal from air or a nitrogen stream) and sometimes in membrane distillation. The later process helps in the separation of azeotropic compositions reducing the costs of distillation processes.
He continued updating this publication to 2010, and it with its research documents and notes, including about half a million press cuttings, is now archived at the Bishopsgate Institute. William Rothenstein (29 January 1872 – 14 February 1945), painter, printmaker, draughtsman, lecturer, writer on art; wrote several critical books and pamphlets, including Goya; the first English monograph on the artist), A Plea for a Wider Use of Artists & Craftsmen and Whither Painting; published three volumes of memoirs: Men and Memories, Vol I and II and Since Fifty. Men and Memories Volume I includes anecdotes about Oscar Wilde and many other friends of Rothenstein's, including Max Beerbohm, James Whistler, Paul Verlaine, Edgar Degas, and John Singer Sargent. Hannah Rothschild (born 22 May 1962), daughter of Jacob Rothschild, 4th Baron Rothschild, author, businesswoman, philanthropist and documentary filmmaker, has written screenplays and journalism, a biography and two novels; serves on charitable and financial boards and is first female to chair the Board of Trustees of the National Gallery in London;liaison trustee for the Tate Gallery;trustee of the Whitechapel Gallery;chair of Yad Hanadiv in Israel; directed films for Saturday Review, Arena and Omnibus; has written for The Times, The New York Times, The Observer, The Guardian, Daily Telegraph, Vanity Fair, Vogue, The Spectator and Harper's Bazaar, Financial Times, Elle, Washington Post and others.
== Activities == The CSCC monitors the quality of testing services and acts as technical experts to evaluate and select methods and instrumentation. They apply their clinical and technical knowledge to assist physicians in selecting and interpreting tests, as well as supporting the laboratory's research and teaching activities. The society also produces publications, including the scientific journal Clinical Biochemistry, a member newsletter CSCC News, and position papers on current issues such as cardiac troponin testing. Special interest groups have been developed to advance knowledge and produce solutions in Clinical Toxicology, Point-Of-Care Testing, Pediatric and Perinatal Biochemistry, Monoclonal Gammopathy, Autoverification of test results, and the Canadian Laboratory Initiative on Paediatric Reference Intervals - CALIPER.
Alexander Butlerov showed in 1861 that the formose reaction created sugars including tetroses, pentoses, and hexoses when formaldehyde is heated under basic conditions with divalent metal ions like calcium. R. Breslow proposed that the reaction was autocatalytic in 1959.
== Treatment == No curative treatment is available for prolidase deficiency at this time, although palliative treatment is possible to some extent. The latter mainly focuses on treating the skin lesions through standard methods and stalling collagen degradation (or boosting prolidase performance, where possible), so as to keep the intracellular dipeptide levels low and give the cells time to resynthesise or absorb what proline they cannot recycle so as to be able to rebuild what collagen does degrade. Patients can be treated orally with ascorbate (a.k.a. vitamin C, a cofactor of prolyl hydroxylase, an enzyme that hydroxylates proline, increasing collagen stability), manganese (a cofactor of prolidase), suppression of collagenase (a collagen degrading enzyme), and local applications of ointments that contain L-glycine and L-proline. The response to the treatment is inconsistent between affected individuals. A therapeutic approach based on enzyme replacement (administering functional prolidase) is under consideration. Due to the weakened immune response in PD cases, it is also of paramount importance to keep any infections under control, often with heavy antibiotics.
Sources: en.wikipedia.org
=== EDTA-dependent agglutination === In some individuals, clinically insignificant antibodies may cause in vitro agglutination of platelets. As a result of platelet clumping, platelet counts reported by automated counters may be much lower than the actual count in the blood because these devices cannot differentiate platelet clumps from individual cells. Pseudothrombocytopenia has been reported in association with the use of EDTA as an anticoagulant, with platelet cold agglutinins, and with multiple myeloma. Other risk factors associated with pseudothrombocytopenia are autoimmune diseases, infections, pregnancy and the treatment with some medications such as low-molecular-weight heparin, valproic acid, insulin, antibiotics and chemotherapy medications like sunitinib. The prevalence of pseudothrombocytopenia in K2-EDTA reported in different studies ranges from 0.03 to 0.27 percent in outpatients, which accounts for 15 to 30 percent of all cases of isolated thrombocytopenia. Tests can mistake small clumps of platelets for leukocytes, thus showing a pseudoleukocytosis in blood counts.
==== Public opinion polls ==== An opinion poll of Canadians conducted by Léger in August 2020 found that a majority (68%) would not take the Russian vaccine if offered a free dose, compared to 14% who said they would take it. When Americans were asked the same question, 59% would not take the Russian vaccine if offered a free dose, compared to 24% who said they would take it. In June 2021, according to a poll conducted by Ost-Ausschuss der Deutschen Wirtschaft (German Eastern Business Association), a majority (60%) of Germans would use the Russian vaccine Sputnik V if they had the opportunity to do so. With 71% approval, the values in East Germany are significantly higher, but with 58% of the respondents there is also a solid majority in West Germany. 38% of respondents, on the other hand, would not want to use Sputnik V. In July 2020, opinion polls suggested around 90% of the Russian population had doubts about the vaccine but by September this had dropped to around half the Russian population. In May 2021, the Levada Center released a poll of 1,614 respondents from 50 regions which showed that 26% of Russians were prepared to be vaccinated with Sputnik V, while 62% were not prepared to be vaccinated. Ten percent of respondents had already been vaccinated.
Tens of thousands of three-dimensional protein structures have been determined by X-ray crystallography and protein nuclear magnetic resonance spectroscopy (protein NMR) and a central question in structural bioinformatics is whether it is practical to predict possible protein–protein interactions only based on these 3D shapes, without performing protein–protein interaction experiments. A variety of methods have been developed to tackle the protein–protein docking problem, though it seems that there is still much work to be done in this field. Other interactions encountered in the field include Protein–ligand (including drug) and protein–peptide. Molecular dynamic simulation of movement of atoms about rotatable bonds is the fundamental principle behind computational algorithms, termed docking algorithms, for studying molecular interactions.
=== Derivation === This section presents a derivation of the equation above for electrons. A similar derivation can be found for the equation for holes. Consider the fact that the number of electrons is conserved across a volume of semiconductor material with cross-sectional area, A, and length, dx, along the x-axis. More precisely, one can say:
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.